52813-U
HybridSPE®-Phospholipid 96-Well Essentials Kit
96-Well Essentials Kit
Synonym(s):
HybridSPE®-Phospholipid
Sign Into View Organizational & Contract Pricing
Select a Size
1 KIT
₹34,780.73
All Photos(2)
Select a Size
Change View
1 KIT
₹34,780.73
About This Item
UNSPSC Code:
41115712
NACRES:
NB.21
Recommended Products
Quality Level
product line
HybridSPE®
technique(s)
solid phase extraction (SPE): suitable
matrix active group
zirconia-based phase
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
HybridSPE-Phospholipid 96 well Plate Essentials Kit that includes one each of the following:
- 96-well HybridSPE-Phospholipid plate (575656-U)
- 96 square well collection plate, 2 mL, polypropylene
- 96 sq. well pierceable cap mat
HybridSPE-Phospholipid technology is a simple and generic sample prep platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis. Biological plasma or serum is first subjected to protein precipitation via the addition and mixing of acidified acetonitrile. Precipitated proteins are then removed by centrifugation and the resulting supernatant is loaded on the HybridSPE-Phospholipid 96-well plate or cartridge which acts as a chemical filter that specifically targets the removal of endogenous sample phospholipids. The phospholipid retention mechanism is based on a highly selective Lewis acid-base interaction between the proprietary zirconia ions functionally bonded to the HybridSPE-Phospholipid stationary phase and the phosphate moiety consistent with all phospholipids. The resulting eluent is ready for immediate LC-MS or LC-MS-MS analysis.
The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
Features and Benefits
- Merges the simplicity of protein precipitation and the selectivity of SPE via the targeted removal of phospholipids
- Reduce ion-suppression through the complete removal of phospholipids and precipitated proteins
- 2-3 step generic procedure
- Minimal to no method development
- Available in 96-well and 1 mL cartridge dimensions
Legal Information
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany
Kit Components Also Available Separately
Product No.
Description
SDS
- 575656-UHybridSPE®-Phospholipid, 96-well Plate, bed wt. 50 mg, volume 2 mL, pk of 1SDS
- 575655-U96 Square Well Pierceable Cap Mats, configured for sealing Discovery SPE and square well collection plates, pk of 50SDS
- 575653-USPE 96-Deep Square Well Collection Plate, well volume 2 mL, polypropylene, pk of 50SDS
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Investigation of endogenous blood plasma phospholipids, cholesterol and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography/mass spectrometry
Ismaiel, O., et al.
Journal of Chromatography. B, Biomedical Applications, 878 (31), 3303-3316 (2010)
Identification and elimination of ion suppression in the quantitative analysis of sirolimus in human blood by LC/ESI-MS/MS
Mano, N., et al.
Journal of Chromatography. B, Biomedical Applications, 879 (13-14), 968-974 (2011)
Improved sensitivity of sedimentary phospholipid analysis resulting from a novel extract cleanup strategy
Zhu, Z., et al.
Organic Geochemistry, 65, 46-52 (2013)
Determination of carboplatin in human plasma using HybridSPE-precipitation along with liquid chromatography-tandam mass spectrometry
Hongliang, J,, et al.
Journal of Chromatography. B, Biomedical Applications, 879 (22), 2162-2170 (2011)
Nora Unceta et al.
Journal of pharmaceutical and biomedical analysis, 70, 529-533 (2012-06-01)
This work proposes a liquid chromatography-electrospray ionization ion trap mass spectrometry (LC-ESI-ITMS) method, for the quantification of sildenafil (SDF), tadalafil (TDF) and vardenafil (VDF) and their metabolites N-desmethylSDF, O-desethylSDF and N-desethylVDF, preceded by a sample preparation step based on protein
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
